Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-757-1 | CAS number: 87-61-6
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with restrictions
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Assessment of teratogenic potential of 1,2,3-, 1,2,4- and 1,2,5-trichlorobenzenes in rats.
- Author:
- Black WD et al
- Year:
- 1 988
- Bibliographic source:
- Bull. Environ. contam. Toxicol 41, 719-726
- Reference Type:
- publication
- Title:
- Evaluation of risks to health from environmental exposure in Canada
- Author:
- Giddings M
- Year:
- 1 994
- Bibliographic source:
- Carcino.Ecotox. Revs. C12, 517-525
- Reference Type:
- publication
- Title:
- A teratological evaluation following oral administration of trichloro- and dichlorobenzene to the rat.
- Author:
- Ruddick VK et al
- Year:
- 1 983
- Bibliographic source:
- Teratology 27, 73A-74A
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- Housing and feeding conditions not reported; exposure too short; number of animals exposed too small; weight of dams recorded only at 22nd day of gestation; food consumption, number of corpora lutea, sex of each foetus not recorded
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 1,2,3-trichlorobenzene
- EC Number:
- 201-757-1
- EC Name:
- 1,2,3-trichlorobenzene
- Cas Number:
- 87-61-6
- Molecular formula:
- C6H3Cl3
- IUPAC Name:
- 1,2,3-trichlorobenzene
- Details on test material:
- - Name of test material (as cited in study report): 1,2,3-trichlorobenzene
- Analytical purity: 99.5%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Duration of treatment / exposure:
- day 6 - day 15 of gestation
- Frequency of treatment:
- once daily
- No. of animals per sex per dose:
- Each groups consisted of approximately 13-14 dams
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Sex: female
Duration of test: until day 22
Results and discussion
Results: maternal animals
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 150 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 600 mg/kg bw/day
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
--None of the animals displayed any signs of toxicity,
--Body weight development was not affected.
--Mortality
300 mg-group: 1 dam died
control group: 1 dam died
--Fetal data
no difference to the concurrent control in
number of dams at term, nimber of dams inseminated, resorptions, dead fetuses, fetal weights, litter size
no viseral or skeletal abnormalities
- Skeletal deviations
(number of pups affected/number of litters affected 150 mg-gr., 300 mg-gr., 600 mg-gr versus control):
Sternal anomalies: 1/1, 1/1, 13/3 versus 1/1
wavy ribs: 0, 1/1, 1/1 versus 1/1
14th rib: 1/1, 0, 0 versus 0
13th rib(short): 1/1, 0, 0 versus 0
----Maternal data (significant changes):
--increase in relative liver weight:
600 mg-gr: 5.8 % versus 5.1% of control
--increase in ADPM activity:
600 mg-gr: 27.3 nanomoles formaldehyde/hr/mg protein versus
22.8 nanomoles formaledhyde/hr/mg protein of control
--decrease in hemoglobin concentration:
500mg-gr, 300 mg-gr: 11.3g/dl, 11.3g/dl versus 12.0g/dl of control
--decrease in hematocrit levels:
600 mg-gr: 31.1% versus 33.3% of controls
--histopathology.
-thyroid, 300 mg-gr and 600 mg-gr: reduction in follicle size accompanied by agular collapse; 600 mg-gr:increased epithelial height accompanied by cytoplasmatic vacuolation
-liver, 300 mg-gr, 600 mg-gr: mild increased periportal cytoplasmic eosinophilia and mild anisokaryosis of hepatocellular nuclei
-spleen
mild increased hematopoiesis in some females (no further information)
--TRCB residues:
only found in traces in the perirenal fat of the 300 mg-gr. and 600 mg-gr consistting of 0.02 and 0.4 ppm, respectively
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
